Arthur C. Mok

Partner

mok-arthur-c
  • JD, The George Washington University Law School, 1997
  • BA, Columbia University, 1994

Qualifications

  • District of Columbia, 1998
  • Chinese (Mandarin)
  • Chambers Asia: Leading Lawyer in Life Sciences, China (2012-2021)
  • IFLR 1000: The Guide to the World’s Leading Financial Law Firms (2013-2022)
  • Asian Legal Business China: Top 15 M&A Lawyers – International Law Firms (2020)
  • China Business Law Journal: The A-List of China’s Top 100 Lawyers (2019)
  • In-House Community: Commended External Counsel of the Year in China (2018)
  • Chambers Asia: Asia's Leading Lawyers in Private Equity, China (2009-2018)
  • Client Choice Awards: the exclusive winner of China Healthcare & Life Sciences (2018)
  • Legal 500 Asia-Pacific: A Leading Individual in Healthcare & Life Science in China (2021)
  • Legal 500 Asia-Pacific: Hall of Fame in Private Equity/Venture Capital, China (2021)
  • Who's Who Legal: Life Sciences (2015-2021)
  • Chambers Global: The World’s Leading Lawyers for Business (2016-2018, 2020) 
  • Asialaw’s Leading Lawyers (2013)
  • Who's Who Legal: Thought Leaders (2021)

Arthur C. Mok

Partner

View the Chinese version.

Arthur is the regional managing partner of Ropes & Gray’s Asia offices, is a member of the firm’s life sciences and private equity groups and is the founder of the firm’s Shanghai office. He has practiced in China since 2004, where he has been advising clients on cross-border mergers and acquisitions, private equity and venture capital financings, equity and cooperative joint ventures, and complex commercial arrangements. Arthur primarily serves multinational pharmaceutical and medical device companies, biotechs and scientific entrepreneurs, and life sciences and healthcare investment funds pursuing opportunities in China. Arthur also devotes his time to advising leading US based hospitals and other healthcare services institutions on their transactions in China. Prior to being based in China, Arthur advised clients on life sciences M&A and private equity transactions in the Washington DC headquarters of a global law firm.

Publications

  • Quoted, “Pharma Frenzy,” Asian Legal Business China (July 2021)

Qualifications

  • District of Columbia, 1998
  • Chambers Asia: Leading Lawyer in Life Sciences, China (2012-2021)
  • IFLR 1000: The Guide to the World’s Leading Financial Law Firms (2013-2022)
  • Asian Legal Business China: Top 15 M&A Lawyers – International Law Firms (2020)
  • China Business Law Journal: The A-List of China’s Top 100 Lawyers (2019)
  • In-House Community: Commended External Counsel of the Year in China (2018)
  • Chambers Asia: Asia's Leading Lawyers in Private Equity, China (2009-2018)
  • Client Choice Awards: the exclusive winner of China Healthcare & Life Sciences (2018)
  • Legal 500 Asia-Pacific: A Leading Individual in Healthcare & Life Science in China (2021)
  • Legal 500 Asia-Pacific: Hall of Fame in Private Equity/Venture Capital, China (2021)
  • Who's Who Legal: Life Sciences (2015-2021)
  • Chambers Global: The World’s Leading Lawyers for Business (2016-2018, 2020) 
  • Asialaw’s Leading Lawyers (2013)
  • Who's Who Legal: Thought Leaders (2021)
Cookie Settings